Literature DB >> 3400634

Regression of membranoproliferative glomerulonephritis type II (dense deposit disease): observations in six children.

P T McEnery1, A J McAdams.   

Abstract

Six children with membranoproliferative glomerulonephritis Type II (MPGN II-dense deposit disease), who were followed an average of 14 years (3.5 to 22 years) and treated continuously with an alternate-day prednisone regimen, have been studied by successive renal biopsies over intervals of 2 to 14 years of disease. All have shown significant reduction in mesangial proliferation and improvement of capillary lumen patency. A change in position of the deposits, from the lamina densa to the lamina rara interna, was demonstrated ultrastructurally in four of the patients, accompanied by reduction in prevalence of deposit in three. This loss of dense deposits, characterized as a process of "dropping off," was complete in the free capillary walls of two of the patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3400634     DOI: 10.1016/s0272-6386(88)80009-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  A case of regression of atypical dense deposit disease without C3 deposition in a child.

Authors:  Min Sun Kim; Pyoung Han Hwang; Mung Jae Kang; Dae-Yeol Lee
Journal:  Korean J Pediatr       Date:  2010-07-31

Review 2.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

Review 3.  Idiopathic membranoproliferative glomerulonephritis in childhood.

Authors:  C D West
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

4.  Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.

Authors:  Samih H Nasr; Anthony M Valeri; Gerald B Appel; Julius Sherwinter; Michael B Stokes; Samar M Said; Glen S Markowitz; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-29       Impact factor: 8.237

5.  Dense deposit disease and the factor H H402 allele.

Authors:  Keith K Lau; Richard J Smith; Peter C Kolbeck; Lavjay Butani
Journal:  Clin Exp Nephrol       Date:  2008-01-26       Impact factor: 2.801

Review 6.  New approaches to the treatment of dense deposit disease.

Authors:  Richard J H Smith; Jessy Alexander; Paul N Barlow; Marina Botto; Thomas L Cassavant; H Terence Cook; Santiago Rodriguez de Córdoba; Gregory S Hageman; T Sakari Jokiranta; William J Kimberling; John D Lambris; Lynne D Lanning; Vicki Levidiotis; Christoph Licht; Hans U Lutz; Seppo Meri; Matthew C Pickering; Richard J Quigg; Angelique L Rops; David J Salant; Sanjeev Sethi; Joshua M Thurman; Hope F Tully; Sean P Tully; Johan van der Vlag; Patrick D Walker; Reinhard Würzner; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2007-08-05       Impact factor: 10.121

7.  Clinico-pathological Profile and Outcome of C-3 Glomerulopathy in Indian Children.

Authors:  Richa Prakash; Uma S Ali; Alpana Ohri; Shashank Nitin Parekhji; Atul Deokar; Shaila Khubchandani
Journal:  Indian J Nephrol       Date:  2020-02-07

Review 8.  Dense deposit disease and C3 glomerulopathy.

Authors:  Thomas D Barbour; Matthew C Pickering; H Terence Cook
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.